Clinical TrialID 8207
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
NCT06132113
Neuroendocrine Neoplasms
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 8207
- Evidence Id
- 8207
- Core Evidence Id
- 8207
- Source Clinical Trial Id
- 8205
- Herb2 Clinical Trial Id
- HBCT008205
- Nct Id
- NCT06132113
- Title
- DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
- Status
- Recruiting
- Phase
- Phase 1
- Study Result
- No
- Study Condition
- Neuroendocrine Neoplasms
- Study Type
- Interventional
- Study Design
- Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: BI 764532|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Cisplatin
- Intervention Allocation
- Non_Randomized
- Intervention Model
- Sequential
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 55
- Outcome Measure
- Part A: Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period, Up to 21 days.|Part B: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment period, Up to 36 months.
- Sponsor Collaborator
- Boehringer Ingelheim
- Funded By
- INDUSTRY
- Location
- Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Northwestern University, Chicago, Illinois, 60611, United States|John Theurer Cancer Center, Hackensack, New Jersey, 07601, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States|Brussels - UNIV Saint-Luc, Bruxelles, 1200, Belgium|Edegem - UNIV UZ Antwerpen, Edegem, 2650, Belgium|INS Paoli-Calmettes, Marseille, 13273, France|Klinikum der Universität München AÖR, München, 81377, Germany|Universitätsklinikum Tübingen, Tübingen, 72076, Germany|Aichi Cancer Center Hospital, Aichi, Nagoya, 464-8681, Japan|National Cancer Center Hospital East, Chiba, Kashiwa, 277-8577, Japan|Osaka International Cancer Institute, Osaka, Osaka, 541-8567, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, 104-0045, Japan|Hospital Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital La Paz, Madrid, 28046, Spain
- Other Id
- 1438-0007|U1111-1292-1400|2023-505870-13-00
- Start Date
- 2023-12-20
- Primary Completion Date
- 2025-11-05
- Completion Date
- 2025-12-01
- First Posted
- 2023-11-15
- Results First Posted
- Last Update Posted
- 2024-10-01
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT06132113
- Title Cn
- Title En
- DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
- Bilingual Status
- semi_complete